Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program

Open Medicine

Volumn 6, Issue 4, 2012, Pages 127-133

  Tobe, Sheldon W ^a   Poirier, Luc ^b   Tremblay, Guy ^b   Lindsay, Patrice ^c   Reid, Debra ^d   Campbell, Norman RC ^e   Khan, Nadia ^f   Quinn, Robert R ^e   Rabi, Doreen ^e  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DEPARTMENT OF NATIONAL DEFENCE   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE MONITORING; CANADA; DISEASE MANAGEMENT; ETHNOLOGY; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; HYPERTENSION; LIFESTYLE; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STATISTICS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CANADA; DISEASE MANAGEMENT; HEALTH EDUCATION; HEALTH PROMOTION; HUMANS; HYPERTENSION; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 84870352475     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Robitaille C, Dai S, Waters C, Loukine L, Bancej C, Quach S, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ 2012;184(1):e49-e56.
2. Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo K. The impact of the aging population on coronary heart disease in the United States. Am J Med 2011;124(9):827-833.
3. Wilkins K, Campbell NR, Joffres MR, McAlister FA, Nichol M, Quach S, et al. Blood pressure in Canadian adults. Health Rep 2010;21(1):37-46.
4. McAlister FA, Feldman RD, Wyard K, Brant R, Campbell NR CHEP Outcomes Research Task Force. The impact of the Canadian Hypertension Education Programme in its first decade. Eur Heart J 2009;30(12):1434-1439.
5. Campbell NRC, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J, et al.; Canadian Hypertension Education Program Outcomes Research Task Force. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension 2009;53(2):128-134.
6. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123(8):933-944.
7. Arthur HM, Suskin N, Bayley M, Fortin M, Howlett J, Heckman G, et al. The Canadian Heart Health Strategy and Action Plan: cardiac rehabilitation as an exemplar of chronic disease management. Can J Cardiol 2010;26(1):37-41.
8. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365(9455):217-223.
9. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002;287(8):1003-1010.
10. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291(11):1342-1349.
11. Warren RE, Marshall T, Padfield PL, Chrubasik S. Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. Br J Gen Pract 2010;60(578):675-680.
12. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011;342:d286.
13. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, et al.; Canadian Hypertension Education Program. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011;27(4):415-433.
14. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, De Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139(4):244-252.
15. Klahr S. Primary and secondary results of the Modification of Diet in Renal Disease study. Miner Electrolyte Metab 1996;22(1-3):138-142.
16. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 2005;142(5):342-351.
17. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123(10):754-762.
18. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al.; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-2431.
19. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 2003;14(7 Suppl 2):S154-S165.
20. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363(10):918-929.
21. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365(9463):939-946.
22. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-1187.
23. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 7: Stratification of risk for progression of kidney disease and development of cardiovascular disease. Am J Kidney Dis 2002;39(2 Suppl 1):S170-S212.
24. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. NICE Clinical Guideline 73. London (UK): Royal College of Physicians; 2008.
25. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755-1762.
26. McKelvie RS, Moe GW, Cheung A, Costigan J, Ducharme A, Estrella-Holder E, et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011;27(3):319-338.
27. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-717.
28. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R EPHESUS Investigators Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118(16):1643-1650.
29. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21.
30. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 2004;217(1-2):53-58.
31. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344(1):3-10.